- Home
- OGEN
OGEN
Oragenics Inc.
as 09-06-2024 4:00pm EST
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SARASOTA |
| Market Cap: | 9.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $7.74 | Next Earning Date: | 08-09-2024 |
| Revenue: | $7,466 | Revenue Growth: | -93.58% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Oragenics Inc. News
OGEN Breaking Stock News: Dive into OGEN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Oragenics, Inc. Announces Closing of Public Offering
MT Newswires
3 days ago
Top Midday Decliners
MT Newswires
3 days ago
Oragenics Stock Falls After Public Offering Priced to Raise $4.45 Million
GlobeNewswire
3 days ago
Oragenics, Inc. Announces Pricing of Public Offering
MT Newswires
17 days ago
Oragenics Completes Spray-Dried Formulation for Concussion Treatment Candidate
GlobeNewswire
17 days ago
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
GlobeNewswire
22 days ago
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
GlobeNewswire
24 days ago
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Compare OGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OGEN Oragenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.